American Health Packaging Recalls Primidone Tablets Due to Acemetacin API Cross-Contamination
American Health Packaging has initiated a Class III recall of 225,000 Primidone Tablets, USP, 50 mg, distributed nationwide, due to trace Acemetacin API cross-contamination. This voluntary action, initiated May 1, 2026, impacts supply chain stability for an essential anti-epileptic, demanding immediate review by procurement and regulatory teams to mitigate disruption and ensure patient safety.
FDA Class III Recall: Primidone Tablets Contaminated with Acemetacin API
American Health Packaging, a key distributor based in Columbus, Ohio, is currently managing a Class III voluntary recall of its Primidone Tablets, USP, 50 mg. This critical action, initiated by Amerisource Health Services LLC on May 1, 2026, stems from the detection of trace amounts of Acemetacin API contaminating the Primidone API. The recall, identified as D-0537-2026, impacts a significant quantity of product: 225,000 tablets distributed across the USA nationwide. Specifically, two lots are affected: Lot 1028739 with an expiration date of December 31, 2027, and Lot 1025622 expiring on June 30, 2027. For procurement directors, this event signals an immediate need to assess existing inventory levels of Primidone and evaluate the resilience of their supply chains. The presence of an undeclared API, even in trace amounts, raises significant concerns about manufacturing controls and cross-contamination prevention strategies. Regulatory affairs heads must scrutinize their quality agreements with distributors and manufacturers, ensuring robust protocols are in place to prevent such incidents and to manage recalls effectively.
Supply Chain Exposure: Implications for Primidone Sourcing and Patient Care
The recall of 225,000 units of Primidone Tablets, USP, 50 mg, directly impacts the availability of an essential anti-epileptic agent (RxCUI: 96304, 198150) across the United States. Primidone, a human prescription drug with application number ANDA084903, is vital for patients managing epilepsy, making any supply disruption a serious concern for healthcare providers and their patients. For supply chain VPs, this event necessitates an urgent review of their reliance on American Health Packaging as a distributor for Primidone and potentially other critical medications. The cross-contamination with Acemetacin API, an anti-inflammatory drug, points to potential systemic issues within the manufacturing or handling processes, such as inadequate cleaning validation between product runs or insufficient segregation of raw materials. This could have broader implications for other products processed in the same facilities or utilizing the same API suppliers. Business development executives should recognize the heightened risk associated with single-source reliance and the imperative to diversify their supplier base to safeguard against similar vulnerabilities, ensuring continuity of care and market stability.
American Health Packaging's Distribution Network and Product Portfolio
American Health Packaging, based in Columbus, Ohio, operates as a significant distributor within the pharmaceutical sector, providing unit-dose and bulk pharmaceutical products. While the specific manufacturing facility for the contaminated Primidone API is not detailed, American Health Packaging is responsible for the distribution of the finished product. The recalled Primidone Tablets, USP, 50 mg, are packaged under Carton NDC: 68084-202-01 and Individual Dose NDC: 68084-202-11, with additional product NDCs 68084-203 and 68084-203-11 also associated with Primidone. As an anti-epileptic agent, Primidone falls under a critical therapeutic class, underscoring the importance of stringent quality control throughout its supply chain. For procurement directors, understanding the role of distributors like American Health Packaging is crucial. While they may not be the primary manufacturer, their responsibility in the distribution chain means they are a critical point of contact for quality assurance and recall management. This event highlights the need for comprehensive due diligence on all partners in the supply chain, from API manufacturers to final distributors, to ensure product integrity and patient safety.
Mitigating Risk: Identifying Alternative Suppliers for Primidone API
Given the ongoing Class III recall of Primidone Tablets, USP, 50 mg, procurement directors must immediately explore and qualify alternative suppliers for Primidone API and finished dosage forms. While specific alternative suppliers are not detailed in the available intelligence, the market for generic anti-epileptic agents typically includes multiple manufacturers. Companies should initiate a robust supplier identification process, focusing on manufacturers with a strong track record of cGMP compliance and comprehensive quality management systems. Key considerations include auditing potential suppliers' cleaning validation protocols, material segregation practices, and impurity testing capabilities to prevent similar cross-contamination events. Geographic diversity in sourcing is also paramount to build resilience against regional disruptions. The qualification timeline for new pharmaceutical suppliers can be extensive, often spanning several months to a year, making proactive engagement critical. Business development executives should view this as an opportunity to strengthen their supply chain resilience, reducing reliance on potentially compromised sources and ensuring uninterrupted access to essential medications for their customers.
Broader Regulatory Landscape: Contamination and Quality Assurance Trends
This recall of Primidone Tablets by American Health Packaging, due to Acemetacin API contamination, aligns with a broader trend of heightened regulatory scrutiny on manufacturing quality and supply chain integrity within the pharmaceutical industry. Recent parallel events underscore the FDA's vigilance: Essential Wellness Pharma faced a Class II recall for Progesterone Injection due to sterility failures on June 15, 2026. Similarly, Spectra Medical Devices' Lidocaine HCl Injection was subject to a Class II recall for sterility assurance deficiencies on June 10, 2026. Furthermore, Guardian Drug Co. Inc. experienced nationwide Class II recalls for Calcium Carbonate Antacids and HyVee Antacid due to metallic contamination, also on June 10, 2026. These incidents collectively signal that regulatory bodies are intensely focused on fundamental manufacturing controls, including preventing cross-contamination, ensuring sterility, and managing impurity profiles. Regulatory affairs heads must interpret these trends as a clear directive to reinforce their quality systems, conduct thorough internal audits, and ensure their contract manufacturing organizations (CMOs) and API suppliers adhere to the highest standards to avoid similar costly and reputation-damaging recalls.
Remediation and Future Outlook for American Health Packaging's Operations
As this Class III recall (D-0537-2026) is ongoing and firm-initiated, American Health Packaging and its manufacturing partners are expected to undertake a comprehensive root cause analysis to identify precisely how the Primidone API became contaminated with trace amounts of Acemetacin API. This investigation will likely focus on shared manufacturing equipment, cleaning procedures, material handling, and quality control testing methodologies. Corrective and Preventive Actions (CAPA) will be mandated, requiring robust enhancements to prevent recurrence. These could include implementing dedicated equipment, stricter segregation of APIs, improved cleaning validation protocols, and enhanced analytical testing for cross-contaminants. For supply chain VPs, monitoring the effectiveness and timeliness of these remediation efforts is crucial. Delays or insufficient corrective actions could lead to further regulatory action, including potential import alerts if foreign manufacturers are involved, or more severe classifications for future incidents. This situation serves as a critical reminder for all industry stakeholders to continuously evaluate and strengthen their quality management systems to ensure product safety and regulatory compliance, thereby protecting both patient health and business continuity.